Literature DB >> 7871097

Glutamate-dopamine interactions in the ventral striatum: role in locomotor activity and responding with conditioned reinforcement.

L H Burns1, B J Everitt, A E Kelley, T W Robbins.   

Abstract

Previous evidence suggests that glutamatergic limbic afferents participate in the potentiation of responding with conditioned reinforcement produced by intra-accumbens d-amphetamine. The present experiments were designed to investigate glutamate-dopamine interactions in the ventral striatum in both conditioned reinforcement and locomotor activity. Glutamate receptor agonists and antagonists were infused into the nucleus accumbens both alone and in combination with 3 micrograms d-amphetamine, and the effects of these interactions on responding with conditioned reinforcement and locomotor activity were measured. The glutamate receptor agonists NMDA, AMPA and quisqualate (agonists at the NMDA, AMPA and metabotropic glutamate receptor subtypes, respectively) and the antagonists AP5 and CNQX, (antagonists at the NMDA and AMPA receptor subtypes, respectively) were used in these investigations. These compounds were used in a dose range of 0.3 to 3 nmol, except CNQX, which was used in 0.2 to 2 nmol doses. While all agonists and antagonists increased locomotor activity when administered alone, the antagonists attenuated the locomotor response to d-amphetamine. In contrast, the agonists AMPA and quisqualate enhanced d-amphetamine-induced locomotor activity, although NMDA interfered with the effects of d-amphetamine. In the conditioned reinforcement paradigm, both the agonists and the antagonists abolished amphetamine's potentiation of responding with conditioned reinforcement, suggesting that the glutamatergic transmission of information about the conditioned reinforcer could be blocked by glutamate receptor antagonists and disrupted by administration of the agonists. The dissociation between the effects of these excitatory amino acids on amphetamine-induced locomotor activity versus their effects on amphetamine's potentiation of responding with conditioned reinforcement provides insight into the nature of the reward enhancement by accumbens dopamine versus its locomotor stimulant effects.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7871097     DOI: 10.1007/bf02245576

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  44 in total

1.  Hippocampal inputs to identified neurons in an in vitro slice preparation of the rat nucleus accumbens: evidence for feed-forward inhibition.

Authors:  C M Pennartz; S T Kitai
Journal:  J Neurosci       Date:  1991-09       Impact factor: 6.167

2.  6-Hydroxydopamine lesions of the nucleus accumbens, but not of the caudate nucleus, attenuate enhanced responding with reward-related stimuli produced by intra-accumbens d-amphetamine.

Authors:  J R Taylor; T W Robbins
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

3.  Role of quisqualic acid receptors in the hypermotility response produced by the injection of AMPA into the nucleus accumbens.

Authors:  P E Shreve; N J Uretsky
Journal:  Pharmacol Biochem Behav       Date:  1988-06       Impact factor: 3.533

4.  The acquisition of responding with conditioned reinforcement: effects of pipradrol, methylphenidate, d-amphetamine, and nomifensine.

Authors:  T W Robbins
Journal:  Psychopharmacology (Berl)       Date:  1978-06-15       Impact factor: 4.530

5.  Hippocampal signal transmission to the pedunculopontine nucleus and its regulation by dopamine D2 receptors in the nucleus accumbens: an electrophysiological and behavioural study.

Authors:  C R Yang; G J Mogenson
Journal:  Neuroscience       Date:  1987-12       Impact factor: 3.590

6.  Differential effects of excitotoxic lesions of the basolateral amygdala, ventral subiculum and medial prefrontal cortex on responding with conditioned reinforcement and locomotor activity potentiated by intra-accumbens infusions of D-amphetamine.

Authors:  L H Burns; T W Robbins; B J Everitt
Journal:  Behav Brain Res       Date:  1993-06-30       Impact factor: 3.332

7.  Selective blockade of N-methyl-D-aspartate (NMDA)-induced convulsions by NMDA antagonists and putative glycine antagonists: relationship with phencyclidine-like behavioral effects.

Authors:  W Koek; F C Colpaert
Journal:  J Pharmacol Exp Ther       Date:  1990-01       Impact factor: 4.030

8.  In vivo modulation of excitatory amino acid receptors: microdialysis studies on N-methyl-D-aspartate-evoked striatal dopamine release and effects of antagonists.

Authors:  D P Carrozza; T N Ferraro; G T Golden; P F Reyes; T A Hare
Journal:  Brain Res       Date:  1992-03-06       Impact factor: 3.252

9.  Sources of presumptive glutamergic/aspartergic afferents to the rat ventral striatopallidal region.

Authors:  T A Fuller; F T Russchen; J L Price
Journal:  J Comp Neurol       Date:  1987-04-15       Impact factor: 3.215

10.  Stimulatory effect of N-methyl aspartate on locomotor activity and transmitter release from rat nucleus accumbens.

Authors:  M H Hamilton; J S De Belleroche; I M Gardiner; L J Herberg
Journal:  Pharmacol Biochem Behav       Date:  1986-11       Impact factor: 3.533

View more
  37 in total

1.  A silent synapse-based mechanism for cocaine-induced locomotor sensitization.

Authors:  Travis E Brown; Brian R Lee; Ping Mu; Deveroux Ferguson; David Dietz; Yoshinori N Ohnishi; Ying Lin; Anna Suska; Masago Ishikawa; Yanhua H Huang; Haowei Shen; Peter W Kalivas; Barbara A Sorg; R Suzanne Zukin; Eric J Nestler; Yan Dong; Oliver M Schlüter
Journal:  J Neurosci       Date:  2011-06-01       Impact factor: 6.167

2.  Dopamine-glutamate interplay in the ventral striatum modulates spatial learning in a receptor subtype-dependent manner.

Authors:  Roberto Coccurello; Alberto Oliverio; Andrea Mele
Journal:  Neuropsychopharmacology       Date:  2012-01-04       Impact factor: 7.853

3.  AMPA/kainate, NMDA, and dopamine D1 receptor function in the nucleus accumbens core: a context-limited role in the encoding and consolidation of instrumental memory.

Authors:  Pepe J Hernandez; Matthew E Andrzejewski; Kenneth Sadeghian; Jules B Panksepp; Ann E Kelley
Journal:  Learn Mem       Date:  2005 May-Jun       Impact factor: 2.460

Review 4.  The nucleus accumbens as part of a basal ganglia action selection circuit.

Authors:  Saleem M Nicola
Journal:  Psychopharmacology (Berl)       Date:  2006-09-16       Impact factor: 4.530

Review 5.  Discrete neurochemical coding of distinguishable motivational processes: insights from nucleus accumbens control of feeding.

Authors:  Brian A Baldo; Ann E Kelley
Journal:  Psychopharmacology (Berl)       Date:  2007-02-23       Impact factor: 4.530

6.  A postsynaptic interaction between dopamine D1 and NMDA receptors promotes presynaptic inhibition in the rat nucleus accumbens via adenosine release.

Authors:  J Harvey; M G Lacey
Journal:  J Neurosci       Date:  1997-07-15       Impact factor: 6.167

Review 7.  Functional mapping of the neural circuitry of rat maternal motivation: effects of site-specific transient neural inactivation.

Authors:  M Pereira; J I Morrell
Journal:  J Neuroendocrinol       Date:  2011-11       Impact factor: 3.627

8.  Impairing effect of amphetamine and concomitant ionotropic glutamate receptors blockade in the ventral striatum on spatial learning in mice.

Authors:  Roberto Coccurello; Alberto Oliverio; Andrea Mele
Journal:  Psychopharmacology (Berl)       Date:  2013-02-05       Impact factor: 4.530

9.  The effects of the mGluR5 receptor antagonist 6-methyl-2-(phenylethynyl)-pyridine (MPEP) on behavioural responses to nicotine.

Authors:  Valeria Tronci; Svetlana Vronskaya; Nicholas Montgomery; Daniela Mura; David J K Balfour
Journal:  Psychopharmacology (Berl)       Date:  2010-04-27       Impact factor: 4.530

10.  Towards a reconceptualization of striatal interactions between glutamatergic and dopaminergic neurotransmission and their contribution to the production of movements.

Authors:  Hélène N David
Journal:  Curr Neuropharmacol       Date:  2009-06       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.